Managing Negative Inotropic Effects in Systolic Dysfunction

Medication Management

Negative inotropic agents should be interrupted or discontinued in patients with systolic dysfunction (LVEF <50%) and worsening heart failure symptoms, though they may be continued if needed for rate or rhythm control of atrial fibrillation on a case-by-case basis. 1, 2
Calcium channel blockers (verapamil, diltiazem), disopyramide, and cardiac myosin inhibitors (mavacamten) are medications with negative inotropic effects that should be managed carefully in patients with reduced ejection fraction. 1, 2
For cardiac myosin inhibitors (mavacamten), discontinuation is recommended if LVEF falls below 50%, with the possibility of restarting at a lower dose if LVEF recovers to >50%. 1, 2

Assessment of left ventricular ejection fraction (LVEF) is essential when managing patients on negative inotropic medications. 1, 2
Patients on negative inotropic agents should have regular assessment of heart failure symptoms and LVEF. 1
Evaluation for obstructive versus non-obstructive physiology is important when managing negative inotropic agents. 1

In patients with hypertrophic cardiomyopathy, negative inotropic agents are often beneficial for symptom management in obstructive HCM but should be discontinued if systolic dysfunction develops. 1, 2
For patients with persistent severe symptoms despite appropriate management, heart transplant evaluation should be considered. 1
Cardiac resynchronization therapy (CRT) should be considered in appropriate patients with reduced ejection fraction. 1
In patients with cardiogenic shock, negative inotropic agents should be avoided. 4, 6
For patients in cardiogenic shock on beta-blockers, levosimendan or phosphodiesterase inhibitors may be considered to reverse negative inotropic effects. 6
Positive inotropic support (dobutamine, milrinone) should be considered for patients with hypotension (SBP <85 mmHg) or hypoperfusion in cardiogenic shock. 6, 7
Combining multiple agents with negative inotropic effects (e.g., beta-blockers with calcium channel blockers) can have synergistic negative effects on cardiac function. 5
In acute myocardial infarction, calcium antagonists should be used cautiously or avoided in patients with heart failure due to their negative inotropic effects. 8
In aortic regurgitation, vasodilator therapy is not indicated for long-term therapy in symptomatic patients with either normal LV function or mild to moderate LV systolic dysfunction who are candidates for valve replacement. 9